Share

February 02, 2021; 96 (5) Article

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven, on behalf of the MSBase Study Group
First published December 28, 2020, DOI: https://doi.org/10.1212/WNL.0000000000011242
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
598

Share

Article Information

vol. 96 no. 5 e783-e797
DOI: 
https://doi.org/10.1212/WNL.0000000000011242
PubMed: 
33372028
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 13, 2019
  • Accepted in final form September 23, 2020
  • First Published December 28, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Tomas Kalincik, MD, PhD,
    2. Ibrahima Diouf, PhD,
    3. Sifat Sharmin, PhD,
    4. Charles Malpas, PhD,
    5. Tim Spelman, MBBS, PhD,
    6. Dana Horakova, MD, PhD,
    7. Eva Kubala Havrdova, MD, PhD,
    8. Maria Trojano, MD,
    9. Guillermo Izquierdo, MD,
    10. Alessandra Lugaresi, MD, PhD,
    11. Alexandre Prat, MD, PhD,
    12. Marc Girard, MD,
    13. Pierre Duquette, MD,
    14. Pierre Grammond, MD,
    15. Vilija Jokubaitis, PhD,
    16. Anneke van der Walt, MD, PhD,
    17. Francois Grand'Maison, MD,
    18. Patrizia Sola, MD, PhD,
    19. Diana Ferraro, MD,
    20. Vahid Shaygannejad, MD,
    21. Raed Alroughani, MD,
    22. Raymond Hupperts, MD, PhD,
    23. Murat Terzi, MD,
    24. Cavit Boz, MD,
    25. Jeannette Lechner-Scott, MD, PhD,
    26. Eugenio Pucci, MD,
    27. Vincent Van Pesch, MD, PhD,
    28. Franco Granella, MD,
    29. Roberto Bergamaschi, MD,
    30. Daniele Spitaleri, MD,
    31. Mark Slee, BMBS, PhD,
    32. Steve Vucic, MBBS, PhD,
    33. Radek Ampapa, MD,
    34. Pamela McCombe, MBBS,
    35. Cristina Ramo-Tello, MD,
    36. Julie Prevost, MD,
    37. Javier Olascoaga, MD,
    38. Edgardo Cristiano, MD,
    39. Michael Barnett, MBBS, PhD,
    40. Maria Laura Saladino, MD,
    41. Jose Luis Sanchez-Menoyo, MD,
    42. Suzanne Hodgkinson, MBBS, PhD,
    43. Csilla Rozsa, MD,
    44. Stella Hughes, MD,
    45. Fraser Moore, MD,
    46. Cameron Shaw, MBBS, PhD,
    47. Ernest Butler, MBBS,
    48. Olga Skibina, MD,
    49. Orla Gray, MD,
    50. Allan Kermode, MBBS, PhD,
    51. Tunde Csepany, MD,
    52. Bhim Singhal, MD,
    53. Neil Shuey, MBBS,
    54. Imre Piroska, MD,
    55. Bruce Taylor, MD, PhD,
    56. Magdolna Simo, MD,
    57. Carmen-Adella Sirbu, MD,
    58. Attila Sas, MD,
    59. Helmut Butzkueven, MBBS, PhD;
    60. on behalf of the MSBase Study Group
  1. Tomas Kalincik, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1) Novartis, (2) Merck, (3) Biogen, (4) Roche, (5) Genzyme-Sanofi, (6) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, compensation for travel and speaker honoraria (2) Biogen, compensation for travel and speaker honoraria (3) Genzyme-Sanofi, compensation for travel and speaker honoraria (4) Teva, speaker honoraria (5) Merck, compensation for travel and speaker honoraria (6) WebMD Global, speaker honoraria (7) Roche, speaker honoraria (8) BioCSL, speaker honoraria

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, editorial board member, since 2018 (2) Neurology and Clinical Practice, editorial board member, since 2020 (3) BMC Neurology, associate editor 2017-2018 (4) Frontiers in Neurology, reviewer editor 2017-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Novartis, (2) Biogen, (3) Genzyme-Sanofi, (4) Teva, (5) Merck, (6) WebMD Global, (7) Roche, (8) BioCSL, (9) Roche

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) University of Melbourne

    Research Support, Foundations and Societies:

    1. (1) National Health and Medical Research Council, (2) MS Research Australia, (3) Medical Research Future Fund, (4) Australian Research Council, (5) MS Society, UK, (6) EDMUS and ARSEP Foundations

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ibrahima Diouf, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sifat Sharmin, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Charles Malpas, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Tim Spelman, MBBS, PhD,
    6. Scientific Advisory Boards:

    1. T. Spelman has received compensation for serving on scientific advisory boards from Biogen

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Dana Horakova, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Support for research activities from Biogen Idec.

    Research Support, Government Entities:

    1. Support by the Czech Ministry of Education project Progres Q27/LF1.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Eva Kubala Havrdova, MD, PhD,
    8. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Maria Trojano, MD,
    9. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Guillermo Izquierdo, MD,
    10. Scientific Advisory Boards:

    1. Bayer, Biogen-Idec, Roche, Novartis, Sanofi Genzyme, Merck Serono, Actelion, Celgene and Teva.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sanofi Genzyme, Roche, Novartis.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Alessandra Lugaresi, MD, PhD,
    11. Scientific Advisory Boards:

    1. (1) Biogen, (2) Merck Serono, (3) Novartis, (4) Roche, (5) Sanofi- Genzyme, (6)Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Biogen, travel and speaker honoraria, (2)Merck Serono, travel and speaker honoraria, (3) Novartis, travel and speaker honoraria, (4) Roche, travel and speaker honoraria, (5) Sanofi-Genzyme, travel and speaker honoraria, (6)Teva, travel and speaker honoraria

    Editorial Boards:

    1. (1) BMC Neurology, associate editor, 2016-2020

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Biogen, (2)Merck Serono, (3) Novartis, (4) Roche, (5) Sanofi- Genzyme and (6)Teva

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Fondazione Italiana Sclerosi Multipla, non profit observational and interventional studies MS-BASE foundation profit and non-profit observational studies

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer (2) Biogen (3) Merck Serono (4) Novartis (5) Roche (6) Sanofi-Genzyme (7) Teva

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) AISM (Associazione Italiana Sclerosi Multipla),

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Alexandre Prat, MD, PhD,
    12. Scientific Advisory Boards:

    1. Biogen, EMD Serono, Teva, Celgene

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, associate editor; (2) Cellular Immunology, associate editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1-CIHR 2-MSSC 3-PMSA

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Marc Girard, MD,
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Pierre Duquette, MD,
    14. Scientific Advisory Boards:

    1. Member of advisory boards for Biogen-Idec, EMD Serono, Novartis, TEVANeuroscience, Genzyme.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Shared patent for a cellular adhesion molecule.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Organisation of CME activities with Biogen-Idec, EMD Serono, Novartis, TEVANeuroscience, Genzyme.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Investigator-initiated study funded by Biogen-Idec, by Novartis,EMD Serono, and by Genzyme.

    Research Support, Government Entities:

    1. CIHR grant (co-investigator). MS Society of Canada (co-investigator).

    Research Support, Academic Entities:

    1. MS Society of Canada.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Pierre Grammond, MD,
    15. Scientific Advisory Boards:

    1. (1) Biogen idec (2) Merk Serono (3) Roche (4) Novartis (5) Alexion

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Funding for travel to congress followed by a speak on a congress, Biogen idec

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen Idec (2) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) MSBase Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Vilija Jokubaitis, PhD,
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono, funding for conference travel. (2) Biogen, speaker honoraria (3) Roche, funding for conference travel and speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Health and Medical Research Council (NHMRC) of Australia Project Grant (1156519), Chief Investigator, 4 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Research Australia (MSRA) fellowship (16-206), Research Fellow, 3 years

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Anneke van der Walt, MD, PhD,
    17. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Francois Grand'Maison, MD,
    18. Scientific Advisory Boards:

    1. Commercial entities: Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Ad board for Alexion and Roche. Honoraria.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial entities: Novartis, Genzyme, Mitsubishi, BiogenIdec, Sanofi, Genetech, Chugai, Opexa Therapeutics

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Patrizia Sola, MD, PhD,
    19. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Diana Ferraro, MD,
    20. Scientific Advisory Boards:

    1. Advisory Board for Biogen, Merck and Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1)Merck Serono, travel and speaker honoraria 2)TEVA Pharmaceutical Industries, travel and speaker honoraria 3)Novartis, travel and speaker honoraria 4)Biogen Idec, travel and speaker honoraria 5)Sanofi-Genzyme, travel honoraria

    Editorial Boards:

    1. BMC Neurology, Associate Editor since 2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Vahid Shaygannejad, MD,
    21. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Raed Alroughani, MD,
    22. Scientific Advisory Boards:

    1. Dr. Alroughani served in scientific advisory boards of Novartis, Bayer, Merck-Sorono, Roche, Biogen, Sanofi-Geznyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr Alroughani received speaker and travel honoraria from Novartis, Bayer, Merck-Sorono, Biogen, Roche, Sanofi-Genzyme and GSK

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received research grant from Biogen, Novartis and Sanofi-Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Raymond Hupperts, MD, PhD,
    23. Scientific Advisory Boards:

    1. I have received honoraria for scientific Advisory boards from: Biogen-Idec, Merck, Genzyme-Sanofi.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received Speaker's honoraria from; Biogen Idec, Genzyme-Sanofi and MERCK.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have received PhD financial support from Biogen-Idec and Merck.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  23. Murat Terzi, MD,
    24. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. received travel grants from Novartis, Bayer Schering, Merck Serono and Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. has participated in clinical trials by Sanofi Aventis, Roche and Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  24. Cavit Boz, MD,
    25. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  25. Jeannette Lechner-Scott, MD, PhD,
    26. Scientific Advisory Boards:

    1. I have served in the past on advisory boards for Bayer Health care, Merck Serono, Biogen, Novartis, CSL, Genzyme- Sanofi, Roche and TEVA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have accepted travel compensation and honoraria from Biogen, Roche, Novartis and Merck Serono.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Scientific project support from (1) Biogen and (2) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Hunter Medical Research Institute University of Newcastle Australia

    Research Support, Foundations and Societies:

    1. John Hunter Hospital Charitable Trust

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  26. Eugenio Pucci, MD,
    27. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. PLOSONE MUTATION RESEARCH - REVIEW IN MUTATION rESEARCH FRONTIERS IN IMMUNOLOGY

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Associazione marchigiana sclerosi multipla e altre malattie neurologiche (local no-profit entity)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  27. Vincent Van Pesch, MD, PhD,
    28. Scientific Advisory Boards:

    1. (1) Biogen (2)Sanofi (3) Roche (4) Novartis Pharma (5) Merck (6) BMS-Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen: travel funding and speaker honoraria (2)Sanofi: travel funding and speaker honoraria (3) Merck: travel funding (4) Roche: travel funding and speaker honoraria (5) Celgene: travel funding

    Editorial Boards:

    1. (1) Acta Neurologica Belgica, associate editor, since 2014.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Sanofi (2)Roche (3)Novartis Pharma (4)Biogen (5) Merck (6) BMS-Celgene

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Sanofi (2) Roche (3) Novartis Pharma

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Fondation Louvain (2) Charcot Foundation Belgium (3) Fonds National de la Recherche Scientifique

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  28. Franco Granella, MD,
    29. Scientific Advisory Boards:

    1. (1)Biogen(2) Novartis (3) Sanofi Genzyme (4) Merck Serono (5) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen (2) Novartis (3) Merck Serono (4)Sanofi Genzyme (5) Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Sanofi Genzyme (2) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  29. Roberto Bergamaschi, MD,
    30. Scientific Advisory Boards:

    1. RB has served on scientific advisory boards for Biogen, Merck- Serono, Novartis, Sanofi-Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. RB received funding for travels and congresses from Biogen, Roche, Merck-Serono, Sanofi-Genzyme, Teva received honoraria for speaking engagement Biogen, Merck- Serono, Novartis, Sanofi-Genzyme

    Editorial Boards:

    1. BMC Neurology, Associated Editor, 2011-2016 Multiple Sclerosis International, Editorial board member, 2011 Clinical Forum, Editorial board member, 2010

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. RB received research support from Bayer, Almirall, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  30. Daniele Spitaleri, MD,
    31. Scientific Advisory Boards:

    1. (1) C.I.C. Edizioni Internazionali

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, (2) Bayer, (3) Biogen, (4) TEVA, (5) Merck- Serono, (6) Sanofi-Aventis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Novartis, (2)Bayer, (3) Sanofi-Aventis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Merck-Serono (2) Novartis (3) Schering

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  31. Mark Slee, BMBS, PhD,
    32. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Australian National Health and Medical Research Council Grant as AI for Pregnancy in Multiple Sclerosis Study.

    Research Support, Academic Entities:

    1. Research Grant funding from Flinders University and Flinders Medical Centre Foundation.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  32. Steve Vucic, MBBS, PhD,
    33. Scientific Advisory Boards:

    1. 1. MND Research Institute of Australia 2. Genzyme-Sanofi Australia 3. Merck Serono Australia 4. Brain Foundation Australia 5. CSL Australia

    Gifts:

    1. 1. CSL Australia- Advisory Board member 2. Merck-Serono- Consultant 3. Sanofi-Genzyme- Honorarium 4. National Health & Medical Research Council-Project Grant

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Web Editor-JNNP 2. Editorial Board Clinical Neurophysiology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Merck Serono Pty Ltd Australia

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. National Health and Medical Research Council-Project Grant (2).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  33. Radek Ampapa, MD,
    34. Scientific Advisory Boards:

    1. Scientific advisory board for Novartis, Roche, Biogen and Merck.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel compensation from Biogen, Merck and Sanofi.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  34. Pamela McCombe, MBBS,
    35. Scientific Advisory Boards:

    1. Scientific advisory board for Biogen, Merck, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Frontiers in Neurology Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  35. Cristina Ramo-Tello, MD,
    36. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Biogen, Genzyme, Novartis, Almirall, Merck, Roche: Travel to attend conferences (2)Spanish Society of Neurology (non-profit entity): Honoraria for speaking engagements

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Fees for medical marketing companies

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Genzyme, Novartis, Almirall

    Research Support, Government Entities:

    1. (1)Instituto de Salud Carlos III. Spain Proyecto FIS PI16/01737

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  36. Julie Prevost, MD,
    37. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. congress, ECTRIMS refund

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  37. Javier Olascoaga, MD,
    38. Scientific Advisory Boards:

    1. Biogen Idec, Genzyme, Novartis, Roche and TEVA

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen-Idec, Bayer-Schering, Genzyme, Merck-Serono, Novartis and Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Dr. Olascoaga serves on scientific advisory boards for Biogen Idec, Genzyme, Novartis, Roche and TEVA; has received speaker honoraria from Biogen-Idec, Bayer-Schering, Genzyme, Merck- Serono, Novartis and Teva and receives research grants from Biogen Idec, Merck Serono, Novartis and Teva.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  38. Edgardo Cristiano, MD,
    39. Scientific Advisory Boards:

    1. (1)Biogen, (1)Merck, (1) Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Genzyme, (1) Novartis, (1) Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  39. Michael Barnett, MBBS, PhD,
    40. Scientific Advisory Boards:

    1. 1.Novartis, scientific advisory board 2.Alexion,scientific advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Merck, Conference Travel (2019 ECTRIMS)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Sydney Neuroimaging Analysis Centre, (2) RxMx Corp.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Novartis, Research Grant support 2. Genzyme-Sanofi, Research Grant Support 3. Biogen, Research Grant Support

    Research Support, Government Entities:

    1. (1) Australian Government, CRC-P Grant, PI, 2018-2021, (2) Australian Government, MRFF Grant, PI, 2020-2023

    Research Support, Academic Entities:

    1. 1. MS Research Australia, Project Grant:

    Research Support, Foundations and Societies:

    1. Nerve Research Foundation, The University of Sydney Stock/Stock Options, Medical Equipment & Materials: (1) RxMx Corp.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  40. Maria Laura Saladino, MD,
    41. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  41. Jose Luis Sanchez-Menoyo, MD,
    42. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, funding for travel to conference. (2) Merck, funding for travel to conference. (3) Biogen, funding for travel to conference. (4) Biogen, speaker honoraria. (5) Novartis, speaker honoraria. (6) Sanofi, speaker honoraria. (7) Merck, speaker honoraria. (8) Almirall, speaker honoraria. (9) Roche, speaker honoraria. (10) Bayer, speaker honoraria. (11) Teva, speaker honoraria.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Biogen, clinical trial. (2) Sanofi, clinical trial. (3) Merck, clinical trial.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  42. Suzanne Hodgkinson, MBBS, PhD,
    43. Scientific Advisory Boards:

    1. Commercial pharma MERCK Novartis Bayer Atara Biogen Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. MERCK - Advisory boards, travel Novartis- Advisory boards, travel Biogen - Advisory boards, travel Roche - Advisory boards, travel Atara - Advisory boards, Travel

    Editorial Boards:

    1. NONE

    Patents:

    1. The role of cytokine IL-5 in antigen specific T cell tolerance

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Monitoring of activated Tcells in cladribine patients 75,0000 Merck

    Research Support, Government Entities:

    1. NH&MRC project grant 2013-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  43. Csilla Rozsa, MD,
    44. Scientific Advisory Boards:

    1. (1)Merck, (2) Biogen, (3) Novartis, (4) Sanofi-Genzyme, (5) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck, (2) Biogen, (3) Novartis, (4) Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  44. Stella Hughes, MD,
    45. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Roche - travel and speaking honoraria (2) Biogen - speaking honoraria (3) Merck Serono - speaking honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  45. Fraser Moore, MD,
    46. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Participated in clinical trial sponsored by Novartis

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  46. Cameron Shaw, MBBS, PhD,
    47. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  47. Ernest Butler, MBBS,
    48. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  48. Olga Skibina, MD,
    49. Scientific Advisory Boards:

    1. Have worked on advisory boards of Roche, Merck, Sanofi Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1.Travel grants from Roche, Sanofi Gezyme and Merck 2. Speaker honoraria from Sanofi Genzime, Merck, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  49. Orla Gray, MD,
    50. Scientific Advisory Boards:

    1. Scientific Advisory Board for Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for travel - Roche Speakers honoraria - Biogen and Merck Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Fast facts: Multiple Sclerosis 4 th Edition

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. One year fundinding for MS Research Registrar from Merck Serono

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  50. Allan Kermode, MBBS, PhD,
    51. Scientific Advisory Boards:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Speakers' Bureaus:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Other activities:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen-Idec; Merck; Novartis; Bayer; Sanofi-Aventis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  51. Tunde Csepany, MD,
    52. Scientific Advisory Boards:

    1. Bayer, Biogen, Merck, Novartis, TEVA

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  52. Bhim Singhal, MD,
    53. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Chairing MS related meeting of Eisai in India during COVID period - non-profit Signature: bssinghal / Bhim Singhal Date: August 13, 2020

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  53. Neil Shuey, MBBS,
    54. Scientific Advisory Boards:

    1. (1) Commercial or non-profit entity: Advisory Boards for Roche, Merck Serono

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial or non-profit entity, travel honoraria: Funding from Biogen, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  54. Imre Piroska, MD,
    55. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen - travel @ accomodation cost to congress, cost of registarion to congress, speaker honoraria (2) Sanofi - travel @ accomodation cost to congress, cost of registarion to congress, speaker honoraria (3) Merck - travel @ accomodation cost to congress, cost of registarion to congress, speaker honoraria (4) Roche - speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  55. Bruce Taylor, MD, PhD,
    56. Scientific Advisory Boards:

    1. Biogen Idec Tecfidera advisory board Australia Novartis Gilenya advisory board Genzyme International advisory board Roche Advisory Board Merck Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding to travel to World Congress of MS Montreal September 2008 from Bayer Schering Pharma Pty Ltd Funding for travel and accommodation from MS Society of Western Australia to speak at their 2008 scientific. meeting. Funding from Bayer Schering Pharma to present a series of lectures in South East Asia March 2008 Invited Guest speaker at Asia pacific MS forum funded by Bayer Schering Pharma Pty Ltd Invited guest speaker INDAPS meeting Melbourne Nov 2008 funded by CSL Pty Ltd Austrlaia. Funding to travel to AAN meeting Seattle 2009 from Bayer Schering Pharma. Funding to travel to ECTRIMS Gothenberg 2010 from Bayer Schering Pharma. Funding to travel to ECTRIMS meeting Lyon France 2012 from Bayer Schering. Funding to travel to AAN San Diego 2013from Novartis. Funding to Travel to ECTRIMS 2013 from Novartis Funding to attend ECTRIMs 2015 from Novartis Funding to attend AN Philadelphia 2019 from Merck Funding to attend ECCTRIMS 2019 From Roche

    Editorial Boards:

    1. Journla of Neurology Neurosrugery and Psychiatry Editorial Board From Jan 2013 Associate Editor BMJ open Neurology 2019 to date. Associate Editor Frontiers I Neurology 2018 - date

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria received from MS society of Western Australia for speaking at the 2008 Scientific meeting

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC australia project grant support.2008-10.490020, 2009 544922 2010 2012 1047180 2013-2016 101295 HRC New Zealand project grant support.2007-8 05/524 National MS Society of USA project grant support Australian research Council and MS Research Australia 2007-9 LP0776744 National MS society of US project grant funding

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  56. Magdolna Simo, MD,
    57. Scientific Advisory Boards:

    1. Scientific advisory board: Merck, Novartis, Sanofi

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for travel and spaeker honoraria: Biogen Idec, Sanofi, Merck

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  57. Carmen-Adella Sirbu, MD,
    58. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  58. Attila Sas, MD,
    59. Scientific Advisory Boards:

    1. MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, Almirall, Roche and Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck Serono, Teva,Genzyme, and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  59. Helmut Butzkueven, MBBS, PhD;
    60. Scientific Advisory Boards:

    1. I serve on Advisory Boards and Steering Committees for studies conducted by Novartis, Roche, Biogen and Merck. My institution (Monash University) is compensated for these activities. I serve on the steering committee of the MSBrain Health Initiative and I am a Board Member of the MSBase Foundation

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board member, MSARD

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. My institution has been compensated for speaking engagements with Roche, Merck, Novartis, and Biogen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. My University receives research support from Biogen, Novartis, Merck and Roche

    Research Support, Government Entities:

    1. My inistitution receives research support from Australian Govt funding agencies NHMRC APP1129189 (CIB, 2018-2021), MRFF 1201062 (CIB , 2020-2024) MRFF 9100003 (CIA, 2019-2021)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. My institution receives research support from MS Research Australia, Trish Foundation Australia

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  60. on behalf of the MSBase Study Group
  1. From CORe (T.K., I.D., S.S., C.M.), Department of Medicine, University of Melbourne; MS Centre (T.K., I.D., S.S., C.M.), Department of Neurology, Royal Melbourne Hospital, Australia; Karolinska Institute (T.S.), Stockholm, Sweden; Department of Neuroscience (T.S., V.J., A.v.d.W., O.S., H.B.), Central Clinical School, Monash University, Melbourne; Burnet Institute (T.S.), Melbourne, Australia; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), General University Hospital and Charles University in Prague, Czech Republic; Department of Basic Medical Sciences, Neuroscience and Sense Organs (M. Trojano), University of Bari, Italy; Hospital Universitario Virgen Macarena (G.I.), Sevilla, Spain; Department of Neuroscience, Imaging and Clinical Sciences (A.L.), University “G. d’Annunzio,” Chieti; Department of Biomedical and Neuromotor Sciences (A.L.), University of Bologna, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; Hopital Notre Dame (A.P., M.G., P.D.), Montreal; CHUM and Universite de Montreal (A.P., M.G., P.D.); CISSS Chaudière-Appalache (P.G.), Levis, Canada; Department of Neurology (V.J., A.v.d.W., O.S., H.B.), Alfred Hospital, Melbourne, Australia; Neuro Rive-Sud (F. Grand'Maison), Quebec, Canada; Department of Neuroscience (P.S., D.F.), Azienda Ospedaliera Universitaria, Modena, Italy; Isfahan University of Medical Sciences (V.S.), Isfahan, Iran; Amiri Hospital (R. Alroughani), Kuwait City, Kuwait; Zuyderland Ziekenhuis (R.H.), Sittard, the Netherlands; Medical Faculty (M. Terzi), 19 Mayis University, Samsun; KTU Medical Faculty Farabi Hospital (C.B.), Karadeniz Technical University, Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle; Department of Neurology (J.L.-S.), John Hunter Hospital, Newcastle, Australia; UOC Neurologia (E.P.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Brussels, Belgium; University of Parma (F. Granella); C. Mondino National Neurological Institute (R.B.), Pavia; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.S.), Italy; Flinders University (M. Slee), Adelaide; Westmead Hospital (S.V.), Sydney, Australia; Nemocnice Jihlava (R. Ampapa), Czech Republic; University of Queensland (P.M.), Brisbane; Royal Brisbane and Women's Hospital (P.M.), Brisbane, Australia; Hospital Germans Trias i Pujol (C.R.-T.), Badalona, Spain; CSSS Saint-Jérôme (J.P.), Canada; Hospital Universitario Donostia (J.O.), Paseo de Begiristain, San Sebastián, Spain; Hospital Italiano (E.C.), Buenos Aires, Argentina; Brain and Mind Centre (M.B.), University of Sydney, Australia; INEBA–Institute of Neuroscience Buenos Aires (M.L.S.), Argentina; Hospital de Galdakao-Usansolo (J.L.S.-M.), Galdakao, Spain; Liverpool Hospital (S. Hodgkinson), Sydney, Australia; Jahn Ferenc Teaching Hospital (C.R.), Budapest, Hungary; Craigavon Area Hospital (S. Hughes), UK; Jewish General Hospital (F.M.), Montreal, Canada; Deakin University (C.S.), Geelong; Monash Medical Centre (E.B.), Melbourne, Australia; South East Trust (O.G.), Belfast, UK; Perron Institute (A.K.), University of Western Australia, Nedlands; Institute of Immunology and Infectious Diseases (A.K.), Murdoch University; Sir Charles Gairdner Hospital (A.K.), Perth, Australia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Bombay Hospital Institute of Medical Sciences (B.S.), Mumbai, India; St Vincents Hospital (N.S.), Fitzroy, Melbourne, Australia; Veszprém Megyei Csolnoky Ferenc Kórház zrt (I.P.), Veszprem, Hungary; Royal Hobart Hospital (B.T.), Australia; Semmelweis University Budapest (M. Simo), Hungary; Central Military Emergency University Hospital (C.-A.S.), Bucharest; Titu Maiorescu University (C.-A.S.), Bucharest, Romania; BAZ County Hospital (A.S.), Miskolc, Hungary; and Box Hill Hospital (H.B.), Melbourne, Australia.
  1. Correspondence
    Dr. Kalincik tomas.kalincik{at}unimelb.edu
View Full Text

Article usage

Article usage: December 2020 to February 2023

AbstractFullPdfSource
Dec 2020381023Highwire
Jan 202117646118Highwire
Feb 20211607142100Highwire
Mar 202110836363Highwire
Apr 20216505041Highwire
May 20215913528Highwire
Jun 20215924634Highwire
Jul 20213551217Highwire
Aug 2021421125Highwire
Sep 20213262319Highwire
Oct 20216662219Highwire
Nov 20214393021Highwire
Dec 20212971615Highwire
Jan 20223441410Highwire
Feb 2022318810Highwire
Mar 20223021313Highwire
Apr 202224348Highwire
May 202222864Highwire
Jun 20222921110Highwire
Jul 2022195910Highwire
Aug 202225975Highwire
Sep 202227966Highwire
Oct 202219962Highwire
Nov 202221787Highwire
Dec 202218321Highwire
Jan 202321275Highwire
Feb 202313654Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles